Skip to main content
Clinical Trials/NCT03216954
NCT03216954
Completed
Early Phase 1

A Human Laboratory Study of n-Acetylcysteine for Alcohol Use Disorder

William Stoops1 site in 1 country14 target enrollmentSeptember 15, 2017

Overview

Phase
Early Phase 1
Intervention
Alcohol
Conditions
Alcohol Use Disorder
Sponsor
William Stoops
Enrollment
14
Locations
1
Primary Endpoint
Number of Alcohol Drinks Chosen
Status
Completed
Last Updated
5 years ago

Overview

Brief Summary

This study will evaluate the behavioral effects of alcohol during placebo and n-acetylcysteine maintenance using sophisticated human laboratory methods.

Registry
clinicaltrials.gov
Start Date
September 15, 2017
End Date
April 23, 2020
Last Updated
5 years ago
Study Type
Interventional
Study Design
Crossover
Sex
All

Investigators

Responsible Party
Sponsor Investigator
Principal Investigator

William Stoops

Professor

University of Kentucky

Eligibility Criteria

Inclusion Criteria

  • able to speak/read English
  • not seeking treatment at the time of the study
  • one binge drinking episode (5+/4+ standard alcoholic drinks per drinking session for men and women, respectively) in the past 30 days
  • recent alcohol use verified by ethyl glucuronide positive urine, as well as fulfillment of DSM-5 diagnostic criteria for alcohol use disorder
  • ECG within normal limits
  • otherwise healthy
  • body mass index of 19-35
  • females using an effective form of birth control and not pregnant or breast feeding
  • judged by the medical staff to be psychiatrically and physically healthy
  • able to abstain from alcohol for 12 hours prior to session

Exclusion Criteria

  • Not provided

Arms & Interventions

Placebo

Subjects will receive oral placebo capsules two times daily.

Intervention: Alcohol

Placebo

Subjects will receive oral placebo capsules two times daily.

Intervention: Placebos

Low Dose n-Acetylcysteine

Subjects will receive 0.6 g oral n-acetylcysteine two times daily.

Intervention: Alcohol

Low Dose n-Acetylcysteine

Subjects will receive 0.6 g oral n-acetylcysteine two times daily.

Intervention: N-acetyl cysteine

High Dose n-Acetylcysteine

Subjects will receive 1.2 g oral n-acetylcysteine two times daily.

Intervention: Alcohol

High Dose n-Acetylcysteine

Subjects will receive 1.2 g oral n-acetylcysteine two times daily.

Intervention: N-acetyl cysteine

Outcomes

Primary Outcomes

Number of Alcohol Drinks Chosen

Time Frame: After at least four days of placebo or n-acetylcysteine maintenance

The reinforcing effects of alcohol were determined using a self-administration procedure in which subjects choose to take previously sampled doses. Reinforcing effects are measured during maintenance on placebo and n-acetylcysteine.

Study Sites (1)

Loading locations...

Similar Trials